Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Neoplasm / drug effects*
  • Drug Therapy, Combination
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 3 / genetics*
  • Leukemia, Prolymphocytic, T-Cell / drug therapy*
  • Male
  • Middle Aged
  • Mutation*
  • Piperidines / therapeutic use*
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Pyrroles / therapeutic use*

Substances

  • INCB018424
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Pyrroles
  • tofacitinib
  • JAK1 protein, human
  • JAK2 protein, human
  • JAK3 protein, human
  • Janus Kinase 1
  • Janus Kinase 2
  • Janus Kinase 3